Overview

* STRATA Q3 2025 revenue fell 21% yr/yr, missing analyst expectations

* Net loss for Q3 2025 reduced to $1.6 mln from $2.1 mln yr/yr

* Company's recurring revenue increased 3% yr/yr, equipment revenue fell 60%

Outlook

* STRATA anticipates revenue growth from expanded CPT codes for reimbursement

* STRATA plans to manage costs and expand patient pool through DTC efforts

Result Drivers

* CPT CODE EXPANSION - Progress in expanding CPT codes for reimbursement expected to triple covered patient population in US

* LITIGATION OUTCOME - Positive developments in lawsuit against LaserOptek, adding new defendants, improving chances for collecting damages

* INTERNATIONAL MARKET SOFTNESS - Revenue decline attributed to instability in international trade policy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $6.90 $8.23

Revenue mln mln (2

Analysts

)

Q3 Net -$1.60

Income mln

Q3 Gross $4.20

Profit mln

Q3 $5.50

Recurrin mln

g

Revenue

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Strata Skin Sciences Inc ( SSKN ) is $8.00, about 79% above its November 12 closing price of $1.68

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)